Vodis Pharmaceuticals Inc (VDQSF) 0.0398 $VDQSF
Post# of 273319
Posted On: 09/20/2016 7:21:47 AM
Vodis Pharmaceuticals Inc (VDQSF) 0.0398 $VDQSF
Vodis Announces Debt Settlement With Director
GlobeNewswire - Tue Jan 19, 7:00AM CST
Vodis Pharmaceuticals Inc. (CSE:VP) (FSE:1JV) ("Vodis" or the "Company"
announces it has agreed to settle a total of $79,274 in outstanding debt owed to a director for expenses and costs incurred by the director on behalf of the Company. The debt will be settled by the issuance to the director of a total of 466,318 common shares of the Company (the "Debt Shares" at a deemed price of $0.17 per share. In consideration of the director's past payment on behalf of the Company of expenses and costs necessary to sustain the Company's operations, the Company has agreed to issue to the director an additional 326,422 common shares of the Company as a bonus (the "Bonus Shares" at a deemed price of $0.17 per Bonus Share. The Debt Shares and the Bonus Shares will be subject to a hold period of four months starting on the date the shares are issued.
Vodis USA Tenant Ready to Deliver Successful Marijuana Crop for Recreational Market
GlobeNewswire - Wed Jan 06, 7:40AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE:VP) (FSE:1JV) and its subsidiary Vodis USA is pleased to announce that its tenant - Our Church International, LLC ("OCI" has reported a successful completion of the first production cycle that exceeds the requirements of the Washington State Liquor and Cannabis Board. OCI further provided a report on one of the flagship strains to the Company that shows a cannabinoid count exceeding 38% that has been confirmed by a third party laboratory. By meeting this milestone, OCI is in a position to start supplying the Washington State recreational market with its high quality product. Vodis has delivered a state-of-the-art production facility to OCI as announced in October of 2015.
Vodis Pharmaceuticals Inc. Closes Final Tranche of Non-Brokered Private Placement
GlobeNewswire - Fri Dec 18, 7:00AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE:VP) (FSE:1JV) announces the closing of the third and final tranche of its previously announced non-brokered private placement of up to 12,000,000 shares by issuing 4,010,000 common shares at a price of $0.10 for gross proceeds of $401,000. The shares issued in the final tranche have a four month and one day hold period expiring on April 18, 2016.
Vodis Pharmaceuticals Inc. Closes Second Tranche of $492,500 of Non-Brokered Financing
GlobeNewswire - Thu Nov 26, 7:00AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE:VP) (FSE:1JV) announces the closing of the second tranche of the previously announced non-brokered private placement of up to $1,200,000. The second tranche consists of a total of 4,925,000 shares of the company's stock at the subscription price of $0.10 per common share for gross proceeds of $492,500 (the "Offering". The shares have a four month and one day hold period expiring on March 21, 2016.
Vodis Pharmaceuticals Inc. Oversubscribes Second Tranche of Non-Brokered Financing
Marketwired - Tue Nov 17, 10:52PM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE: VP)(FRANKFURT: 1JV) announces that the non-brokered private placement (the "Offering", previously announced on November 2, 2015, of up to 7,500,000 common shares of the Company at a subscription price of $0.10 per common share for aggregate gross proceeds of $750,000 has been oversubscribed. Vodis announces that it is increasing the private placement by an additional 4,500,000 common shares for a total of 12,000,000 shares to raise up to $1,200,000.
Vodis Pharmaceuticals Inc. Closes First Tranche of $217,000 of Non-Brokered Financing
Thomson Reuters ONE - Mon Nov 09, 7:55AM CST
Vodis Pharmaceuticals Inc. / Vodis Pharmaceuticals Inc. Closes First Tranche of $217,000 of Non-Brokered Financing . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Vodis Pharmaceuticals Inc. Announces $750,000 Non-Brokered Financing
GlobeNewswire - Mon Nov 02, 7:01AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE:VP) (FSE:1JV) wishes to announce a non-brokered private placement offering up to 7,500,000 common shares of the Company at a subscription price of $0.10 per common share for aggregate gross proceeds of $750,000 (the "Offering".
Vodis Pharmaceuticals Provides Shareholder Update
GlobeNewswire - Tue Oct 20, 7:00AM CDT
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis" (CSE:VP) (FSE:1JV) is pleased to provide an operational update and announce plans to maximize production for the tenant at its Bellingham, Washington based production facility. In addition, the Company is pleased to announce that it has entered into negotiations with another licensed producer to initiate production in the second building situated on its Bellingham property.
Vodis Effects 25 Year Facility Lease With Licensed Producer/Processor and Expands Washington State Operations
GlobeNewswire - Mon Oct 05, 1:50PM CDT
Vodis Pharmaceuticals Inc. (CSE:VP) (FSE:1JV) ("Vodis Pharmaceuticals" and its wholly-owned subsidiary, Vodis USA, Inc., a Washington corporation ("Vodis" or the "Company" are pleased to announce Vodis intends to expand its Washington State operations in multiple ways.
VODIS Production and Processing Facility Passes Washington State Liquor and Cannabis Board Inspection - Tenant to Begin Recreational Marijuana Business Operations Immediately.
TheNewswire.ca - Wed Sep 23, 7:00AM CDT
(via Thenewswire.ca)
Vodis Pharmaceuticals Inc. Closes Non-Brokered Private Placement
TheNewswire.ca - Wed Sep 16, 9:11AM CDT
(via Thenewswire.ca)
Vodis Appoints Tammy Gillis as New Chief Financial Officer
TheNewswire.ca - Sat Sep 05, 6:55PM CDT
(via Thenewswire.ca)
Vodis Announces Debt Settlement
TheNewswire.ca - Mon Aug 24, 4:00PM CDT
(via Thenewswire.ca)
Vodis to Receive Permission for an Inspection in Washington State once New Air Flow System is Installed
TheNewswire.ca - Fri Jul 24, 9:17AM CDT
(via Thenewswire.ca)
Vodis Announces Changes To The Board Of Directors
TheNewswire.ca - Sun Jun 21, 4:37PM CDT
(via Thenewswire.ca)
Vodis Signs Agreement With Washington State Marijuana Tier 2 Tenant
ACCESSWIRE - Tue Apr 21, 7:04AM CDT
VANCOUVER, BC / ACCESSWIRE / April 21, 2015 / Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV /Q:VDQSF) is pleased to announce its' subsidiary, Vodis USA, has signed a sublease agreement and we are moving forward with the development of a Tier 2 Marijuana Production and Processing facility as required by the state law and governed by the Washington State Liquor Board (WSLB) The Vodis facility is expected to be retrofitted to the Vodis production standards within the next 12 weeks and production to begin thereafter..
Vodis Pharmaceuticals Inc. Closes Final Tranche of $226,000 of Non-Brokered Private Placement
TheNewswire.ca - Tue Apr 14, 3:01PM CDT
(via Thenewswire.ca)
Vodis Announces Debt Settlement With Director
GlobeNewswire - Tue Jan 19, 7:00AM CST
Vodis Pharmaceuticals Inc. (CSE:VP) (FSE:1JV) ("Vodis" or the "Company"
announces it has agreed to settle a total of $79,274 in outstanding debt owed to a director for expenses and costs incurred by the director on behalf of the Company. The debt will be settled by the issuance to the director of a total of 466,318 common shares of the Company (the "Debt Shares" at a deemed price of $0.17 per share. In consideration of the director's past payment on behalf of the Company of expenses and costs necessary to sustain the Company's operations, the Company has agreed to issue to the director an additional 326,422 common shares of the Company as a bonus (the "Bonus Shares" at a deemed price of $0.17 per Bonus Share. The Debt Shares and the Bonus Shares will be subject to a hold period of four months starting on the date the shares are issued. Vodis USA Tenant Ready to Deliver Successful Marijuana Crop for Recreational Market
GlobeNewswire - Wed Jan 06, 7:40AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE:VP) (FSE:1JV) and its subsidiary Vodis USA is pleased to announce that its tenant - Our Church International, LLC ("OCI" has reported a successful completion of the first production cycle that exceeds the requirements of the Washington State Liquor and Cannabis Board. OCI further provided a report on one of the flagship strains to the Company that shows a cannabinoid count exceeding 38% that has been confirmed by a third party laboratory. By meeting this milestone, OCI is in a position to start supplying the Washington State recreational market with its high quality product. Vodis has delivered a state-of-the-art production facility to OCI as announced in October of 2015. Vodis Pharmaceuticals Inc. Closes Final Tranche of Non-Brokered Private Placement
GlobeNewswire - Fri Dec 18, 7:00AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE:VP) (FSE:1JV) announces the closing of the third and final tranche of its previously announced non-brokered private placement of up to 12,000,000 shares by issuing 4,010,000 common shares at a price of $0.10 for gross proceeds of $401,000. The shares issued in the final tranche have a four month and one day hold period expiring on April 18, 2016. Vodis Pharmaceuticals Inc. Closes Second Tranche of $492,500 of Non-Brokered Financing
GlobeNewswire - Thu Nov 26, 7:00AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE:VP) (FSE:1JV) announces the closing of the second tranche of the previously announced non-brokered private placement of up to $1,200,000. The second tranche consists of a total of 4,925,000 shares of the company's stock at the subscription price of $0.10 per common share for gross proceeds of $492,500 (the "Offering". The shares have a four month and one day hold period expiring on March 21, 2016. Vodis Pharmaceuticals Inc. Oversubscribes Second Tranche of Non-Brokered Financing
Marketwired - Tue Nov 17, 10:52PM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE: VP)(FRANKFURT: 1JV) announces that the non-brokered private placement (the "Offering", previously announced on November 2, 2015, of up to 7,500,000 common shares of the Company at a subscription price of $0.10 per common share for aggregate gross proceeds of $750,000 has been oversubscribed. Vodis announces that it is increasing the private placement by an additional 4,500,000 common shares for a total of 12,000,000 shares to raise up to $1,200,000. Vodis Pharmaceuticals Inc. Closes First Tranche of $217,000 of Non-Brokered Financing
Thomson Reuters ONE - Mon Nov 09, 7:55AM CST
Vodis Pharmaceuticals Inc. / Vodis Pharmaceuticals Inc. Closes First Tranche of $217,000 of Non-Brokered Financing . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Vodis Pharmaceuticals Inc. Announces $750,000 Non-Brokered Financing
GlobeNewswire - Mon Nov 02, 7:01AM CST
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE:VP) (FSE:1JV) wishes to announce a non-brokered private placement offering up to 7,500,000 common shares of the Company at a subscription price of $0.10 per common share for aggregate gross proceeds of $750,000 (the "Offering". Vodis Pharmaceuticals Provides Shareholder Update
GlobeNewswire - Tue Oct 20, 7:00AM CDT
Vodis Pharmaceuticals Inc. (the "Company" or "Vodis"
(CSE:VP) (FSE:1JV) is pleased to provide an operational update and announce plans to maximize production for the tenant at its Bellingham, Washington based production facility. In addition, the Company is pleased to announce that it has entered into negotiations with another licensed producer to initiate production in the second building situated on its Bellingham property. Vodis Effects 25 Year Facility Lease With Licensed Producer/Processor and Expands Washington State Operations
GlobeNewswire - Mon Oct 05, 1:50PM CDT
Vodis Pharmaceuticals Inc. (CSE:VP) (FSE:1JV) ("Vodis Pharmaceuticals"
and its wholly-owned subsidiary, Vodis USA, Inc., a Washington corporation ("Vodis" or the "Company" are pleased to announce Vodis intends to expand its Washington State operations in multiple ways. VODIS Production and Processing Facility Passes Washington State Liquor and Cannabis Board Inspection - Tenant to Begin Recreational Marijuana Business Operations Immediately.
TheNewswire.ca - Wed Sep 23, 7:00AM CDT
(via Thenewswire.ca)
Vodis Pharmaceuticals Inc. Closes Non-Brokered Private Placement
TheNewswire.ca - Wed Sep 16, 9:11AM CDT
(via Thenewswire.ca)
Vodis Appoints Tammy Gillis as New Chief Financial Officer
TheNewswire.ca - Sat Sep 05, 6:55PM CDT
(via Thenewswire.ca)
Vodis Announces Debt Settlement
TheNewswire.ca - Mon Aug 24, 4:00PM CDT
(via Thenewswire.ca)
Vodis to Receive Permission for an Inspection in Washington State once New Air Flow System is Installed
TheNewswire.ca - Fri Jul 24, 9:17AM CDT
(via Thenewswire.ca)
Vodis Announces Changes To The Board Of Directors
TheNewswire.ca - Sun Jun 21, 4:37PM CDT
(via Thenewswire.ca)
Vodis Signs Agreement With Washington State Marijuana Tier 2 Tenant
ACCESSWIRE - Tue Apr 21, 7:04AM CDT
VANCOUVER, BC / ACCESSWIRE / April 21, 2015 / Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV /Q:VDQSF) is pleased to announce its' subsidiary, Vodis USA, has signed a sublease agreement and we are moving forward with the development of a Tier 2 Marijuana Production and Processing facility as required by the state law and governed by the Washington State Liquor Board (WSLB) The Vodis facility is expected to be retrofitted to the Vodis production standards within the next 12 weeks and production to begin thereafter..
Vodis Pharmaceuticals Inc. Closes Final Tranche of $226,000 of Non-Brokered Private Placement
TheNewswire.ca - Tue Apr 14, 3:01PM CDT
(via Thenewswire.ca)
(0)
(0)